Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?-Reference-Cited by-同舟云学术

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?

Published:2016-11 Issue: Volume:50 Page:23-34
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Meulendijks Didier,Cats Annemieke,Beijnen Jos H.,Schellens Jan H.M.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference98 articles.

1. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy;Rich;J Clin Oncol,2004

2. European Public Assessment Report Capecitabine. European Medicines Agency (EMA); 2005. .

3. Scrip world pharmaceutical news;Scrip’s Cancer Chemotherapy Report,2002

4. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study;Hoff;J Clin Oncol,2001

5. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study;Van Cutsem;J Clin Oncol,2001

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis;Clinica Chimica Acta;2024-07

2. Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia;Frontiers in Pharmacology;2023-09-08

3. Feasibility of DPYD Genotyping in Australian Cancer Patients;2023-06-09

4. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center;American Journal of Health-System Pharmacy;2023-05-26

5. Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations;Archive of Clinical Cases;2023-05-18